Scarica l'app Stockscreener
7.42
15.10%
-1.32
Pre-mercato:
7.68
0.26
+3.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Investing News Network
Aligos Therapeutics jumps 22% on Greater China deal for Hepatitis B drug (ALGS:NASDAQ) - Seeking Alpha
Aligos Therapeutics stock surges on China licensing deal - Investing.com
Aligos Therapeutics (ALGS) Secures Licensing Deal for Hepatitis B Treatment - GuruFocus
Aligos licenses hepatitis B drug to Amoytop for $25m upfront - Investing.com Canada
More than 90 million live with HBV in Greater China; Aligos signs deal - Stock Titan
Aligos receives FDA fast track designation for hepatitis B drug By Investing.com - Investing.com Australia
Responsive Playbooks and the ALGS Inflection - Stock Traders Daily
Aligos Therapeutics (ALGS) Updates on Phase 2 Hepatitis B Study Results - GuruFocus
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aligos Advances HBV Candidate With Interim Data, Fast Track - TipRanks
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation - Investing News Network
Aligos receives FDA fast track designation for hepatitis B drug - Investing.com
Aligos Reports DSMB OK to Expand HBeAg- Cohort; FDA Grants Fast Track for Pevifoscorvir - TradingView — Track All Markets
Aligos Therapeutics (ALGS) wins FDA Fast Track as HBV trial advances - Stock Titan
Aligos Therapeutics announces first interim analysis results from the phase 2 B-Supreme study of pevifoscorvir sodium in participants with chronic hepatitis B virus infection and grant of FDA fast track designation - marketscreener.com
Aligos Therapeutics Announces First Interim Analysis Results From The Phase 2 B-Supreme Study Of Pevifoscorvir Sodium In Participants With Chronic Hepatitis B Virus Infection And Grant Of FDA Fast Track Designation - TradingView — Track All Markets
Hepatitis B study avoids futility as FDA grants fast-track status - Stock Titan
Total debt per share of Aligos Therapeutics, Inc. – MUN:5WK0 - TradingView — Track All Markets
Aug Mood: Can Aligos Therapeutics Inc continue delivering strong returnsCEO Change & Safe Entry Point Alerts - baoquankhu1.vn
Understanding the Setup: (ALGS) and Scalable Risk - Stock Traders Daily
ALGS.O PE Ratio & Valuation, Is ALGS.O Overvalued - Intellectia AI
ALGS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Tangible book value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Net current asset value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Decliners Report: What are Aligos Therapeutics Incs technical support levels2026 Snapshot & Daily Volume Surge Signals - baoquankhu1.vn
Cash per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Book value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
ALGS PE Ratio & Valuation, Is ALGS Overvalued - Intellectia AI
If You Invested $1,000 in Fractyl Health (GUTS) - Stock Titan
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $41.50 Average PT from Analysts - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Raised to Strong-Buy at Jefferies Financial Group - Defense World
Earnings Risk: Can Aligos Therapeutics Inc continue delivering strong returns2026 Action & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
WestPark Capital initiates coverage of Aligos Therapeutics (ALGS) with buy recommendation - MSN
Insider Sell: Will Aligos Therapeutics Inc outperform its industry peers2026 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn
Bull Run: What analysts say about Aligos Therapeutics Inc stockWeekly Profit Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
The Technical Signals Behind (ALGS) That Institutions Follow - Stock Traders Daily
Aug PostEarnings: Will Aligos Therapeutics Inc outperform its industry peers2026 News Drivers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Aligos Therapeutics (ALGS) 8th Annual MASH Investor Conference Summary - Quartr
If You Invested $1,000 in Aligos Therapeutics, Inc. (ALGS) - Stock Titan
ALGS Technical Analysis & Stock Price Forecast - intellectia.ai
Activity Recap: Can Aligos Therapeutics Inc weather a recessionTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
Jefferies Lowers Price Target for Aligos Therapeutics (ALGS) to $48 | ALGS Stock News - GuruFocus
Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential - Investing.com India
Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential By Investing.com - Investing.com South Africa
Nikhil Aneja Net Worth (2026) - GuruFocus
What is HC Wainwright’s Estimate for ALGS Q1 Earnings? - Defense World
Precision Trading with Aligos Therapeutics Inc. (ALGS) Risk Zones - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
Aligos Therapeutics (ALGS) officer awarded 23,310 stock options at $7.03 strike - Stock Titan
Aligos Therapeutics (ALGS) accounting officer granted 9,450 stock options at $7.03 - Stock Titan
Aligos Therapeutics (ALGS) awards 37,485 stock options to officer Calhoun - Stock Titan
Aligos Therapeutics (ALGS) CEO granted stock options for 105,840 shares - Stock Titan
HC Wainwright & Co. Reiterates Buy Rating on ALGS with $50 Price Target | ALGS Stock News - GuruFocus
Dip Buying: Can Aligos Therapeutics Inc weather a recessionWeekly Earnings Recap & Risk Managed Trade Strategies - baoquankhu1.vn
Aligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street Zen - Defense World
Aug Highlights: Can Aligos Therapeutics Inc weather a recessionMarket Rally & Daily Entry Point Alerts - baoquankhu1.vn
Aligos Therapeutics Earnings Report: Q4 Overview - Sahm
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results - Bitget
Aligos Therapeutics (ALGS) Reports Lower Q4 Revenue and Advances Key Studies - GuruFocus
ALIGOS THERAPEUTICS ($ALGS) Releases Q4 2025 Earnings - Quiver Quantitative
Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing - TradingView
Aligos Therapeutics Q4 net loss narrows - TradingView
Growth Report: Will Aligos Therapeutics Inc benefit from current market trendsM&A Rumor & High Win Rate Trade Alerts - baoquankhu1.vn
Big loss reduction as Aligos (NASDAQ: ALGS) advances HBV and obesity pipeline - Stock Titan
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):